← BioTransfer GEO Dataset Finder
GEO series

Curative treatment of advanced, poorly immunogenic metastatic murine cancer models using an in situ vaccine, low-dose radiopharmaceutical, and immune checkpoint inhibition

GSE304809 Mus musculus (mouse) RNA-seq (gene expression) 14 samples Submitted 2026/07/02 Platform GPL34290
At a glance

RNA-seq (gene expression) · mouse · 14 samples

What it is
RNA-seq (gene expression)Gene activity measured by sequencing. The summary does not mention single-cell work, so this is most likely bulk: one average per sample, the usual starting point for comparing groups.
Organism
Mus musculus (mouse)
Samples
14 samples: 5 conditions, mostly in triplicateGroups are read from the sample names, not from the paper. Check the list below.
Data you can get
A processed table (series matrix) and supplementary files from NCBI; the raw sequencing reads from ENA. Which of these hold counts depends on the study, so check the file list.
Summary (written by the submitters)
Background Focal tumor radiation may prime adaptive anti-tumor immunity and this can be augmented by combination with intratumoral delivery of immune adjuvants. However, the abscopal propagation of anti-tumor immune response from such in situ vaccine (ISV) approaches is not consistently achieved in metastatic disease. Targeted radionuclide therapy (TRT) can deliver radiation to all tumor site in metastatic settings and low dose TRT can promote the clonal expansion and propagation of T cell-mediated anti-tumor immune response.
Read the full summary ↓
We hypothesized that combining ISV to prime and low-dose TRT to propagate anti-tumor immunity could promote response to dual immune checkpoint blockade (DCP; anti-PD-L1 and anti-CTLA-4) in murine models of poorly immunogenic metastatic disease. Methods: C57BL/6 mice were engrafted with a primary tumor (right flank), a secondary tumor (left flank), and intravenously injected tumor cells to model advanced metastatic disease using the syngeneic MOC2 head and neck squamous cell carcinoma model or the B78 melanoma model. Mice were randomized to receive monotherapy or double or triple combinations of low-dose TRT, ISV targeting the primary tumor, and DCP. Tumor growth and survival were measured and mice rendered tumor-free mice were re-challenged with tumor engraftment to assess immune memory. Immune response was assessed by immunohistochemistry, flow cytometry, and quantitative PCR. Results: In two poorly immunogenic, syngeneic murine tumor models of advanced metastatic cancer, when compared to dual combinations or monotherapies, a triple combination of TRT+DCP+ISV enabled eradication of bulky well-established tumors, prevented development of lung metastases from circulating tumor cells (4 of 7 mice with circulating B16 melanoma and 14 of 15 mice with circulating MOC2 HNSCC developed no lung metastases), and extended survival (p < 0.01). This combination conferred T cell-dependent, tumor-specific immune memory, enabling uniform rejection of tumor re-engraftment (0% vs 100% for both B78 melanoma and MOC2 re-engraftment in disease-free triple-therapy treated mice vs age matched control mice). TRT+DCP+ISV activated both innate and adaptive immune response pathways in the primary and secondary tumors. Conclusions: Combining ISV and low-dose TRT is a promising approach to prime and propagate anti-tumor immunity and to promote response to checkpoint inhibition in settings of poorly immunogenic metastatic cancers.
This dataset
Open GSE304809 in finder → Find more mouse RNA-seq datasets →
Download · which file do I need?

Direct links to NCBI and ENA, no account and no request form. Pick by what you want to do: take the small processed table to look, the supplementary files to re-analyse, or the original raw data to start over.

1 · Just have a look

Processed table

The series matrix: one table of values per sample as the submitters processed it. The smallest download, and it opens in Excel or R. Start here to see what the data look like.

Series matrix ↓
2 · Re-analyse it

Supplementary files

The count tables and other files the authors uploaded. Take only the samples you need, or the whole study as GSE304809_RAW.tar (it can run to tens of gigabytes).

All supplementary files ↗ Whole study · RAW.tar ↓
3 · Start from the raw reads

Raw sequencing reads

The original FASTQ files, straight from the sequencer, held at ENA. Large, and you align them yourself, so only choose this if you need to re-process the study from scratch.

Raw reads on ENA ↗

What the files usually look like: For RNA-seq the counts are usually a table among the supplementary files (look for 'counts', 'expression', 'FPKM' or 'TPM' in the file name). The series matrix of a sequencing study is sometimes nearly empty.

Also filed as BioProject PRJNA1302769 and SRA study SRP607255. Searching any of these in the dataset finder brings you back here.

NCBI GEO page ↗
Study design
5 conditions, mostly in triplicate
B78 melanoma cells, PBS control, week 3 ×3 B78 melanoma cells, 20uCi+DCP, week 3 ×3 B78 melanoma cells, ISV+DCP, week 3 ×3 B78 melanoma cells, 20uCi+ISV+DCP, week 3 ×3 B78 melanoma cells, 20uCi+ISV, week 3 ×2

Supports a between-group comparison across 14 samples.

How we read this: 5 replicated groups read from 14 sample titles; they account for 14 of them. These groups are guessed from the sample names, not taken from the paper, so check them against the sample list below before relying on them.

Samples in this study
Datasets on a similar topic

Search all mouse RNA-seq datasets in GEO →

Share this dataset

Metadata from NCBI GEO, cached and refreshed periodically — the NCBI page above is authoritative. Downloads link straight to NCBI/ENA; nothing is proxied through BioTransfer.